xlr-12 xlr-12 xlr-12 is an indole-based synthetic cannabinoid drug that was invented by abbott laboratories in 2006. it is an analogue of xlr-11 where the 5-fluoropentyl chain has been replaced with a 4,4,4-trifluorobutyl chain. xlr-12 is relatively highly selective for the cb2 receptor, with a ki of 0.09 nm and 167x selectivity over the related cb1 receptor, however it still retains appreciable affinity for cb1 with a ki of 15 nm. xlr-12legal statuslegal status ca: schedule ii identifiers iupac name (2,2,3,3-tetramethylcyclopropyl)methanone cas number895155-78-9 ypubchem cid11559386chemspider9734160uniieg79k9xqf5chemical and physical dataformulac20h24f3nomolar mass351.413 g·mol−13d model (jsmol)interactive image smiles o=c(c1c(c1(c)c)(c)c)c1cn(c2c1cccc2)cccc(f)(f)f inchi inchi=1s/c20h24f3no/c1-18(2)17(19(18,3)4)16(25)14-12-24(11-7-10-20(21,22)23)15-9-6-5-8-13(14)15/h5-6,8-9,12,17h,7,10-11h2,1-4h3key:pexykzytxieeob-uhfffaoysa-n legal status xlr-12 is illegal in hungary and japan.